Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call

August 11, 2025 8:00 AM ET

Company Participants

• Dale A. Sander – CFO, Chief Corporate Development Officer & Treasurer
• Laura E. Niklason – Founder, President, CEO & Director
• William John Scheessele – Chief Commercial Officer

Conference Call Participants

• Bruce David Jackson – The Benchmark Company, LLC, Research Division
• Joshua Thomas Jennings – TD Cowen, Research Division
• Ryan Benjamin Zimmerman – BTIG, LLC, Research Division
• Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
• Thomas Johnson – Lifesci Advisors, LLC

Operator

Good morning, ladies and gentlemen, and welcome to the Humacyte Second Quarter 2025 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Tom Johnson with Lifesci Advisors. Please go ahead.

Thomas Johnson

Thank you, operator. Before we proceed with the call, I’d like to remind everyone that certain statements during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law.

Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which may be accessed from the Investor page of the Humacyte website. Joining me today on today’s call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate Development Officer.